Nonrulemaking

Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry.

🏛 Food and Drug Administration (FDA)FDA-2026-P-6737

Artificial Intelligence Pharmaceutical Policy Product Safety & Recalls

Documents

Total comments

all analyzed

Comment status

Open

Last activity

—

In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

All 45 Supporting & Related Material 43 Other 2

📄 Primary document

OtherJun 15, 2026

Citizen Petition from Regina Sutton

No comment period

Open →

Other· Jun 15, 2026
Acknowledgement Letter from FDA DMB to Regina Sutton→
No comment period
Supporting & Related Material· Jun 15, 2026
Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment→
Supporting & Related Material· Jun 15, 2026
Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling→
Supporting & Related Material· Jun 15, 2026
Reference 3 - Gadolinium retention effect on macrophages→
Supporting & Related Material· Jun 15, 2026
Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway→
Supporting & Related Material· Jun 15, 2026
Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents→
Supporting & Related Material· Jun 15, 2026
Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents→
Supporting & Related Material· Jun 15, 2026
Reference 8 - Repeated gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 9 - Gadolinium Mitochondrial Toxicity→
Supporting & Related Material· Jun 15, 2026
Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity→
Supporting & Related Material· Jun 15, 2026
Reference 11 - On the interaction of muscle actin with gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity→
Supporting & Related Material· Jun 15, 2026
Reference 13 - Prepubertal exposure to gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI→
Supporting & Related Material· Jun 15, 2026
Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction→
Supporting & Related Material· Jun 15, 2026
Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast→
Supporting & Related Material· Jun 15, 2026
Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility→
Supporting & Related Material· Jun 15, 2026
Reference 18 - Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory→
Supporting & Related Material· Jun 15, 2026
Reference 19 - Gadolinium-based contrast agent toxicity→
Supporting & Related Material· Jun 15, 2026
Reference 20 - Human Hair as a Possible Surrogate Marker of Retained Tissue→
Supporting & Related Material· Jun 15, 2026
Reference 21 - Influence blocking by Gadolinium in Calcium Diffusion→
Supporting & Related Material· Jun 15, 2026
Reference 22 - Gadolinium deposition in bone tissues after contrast-enhanced→
Supporting & Related Material· Jun 15, 2026
Reference 23 - Assessment of gadolinium and iodine concentrations in kidney stones→
Supporting & Related Material· Jun 15, 2026
Reference 24 - Effects of Gadolinium-Based MRI Contrast→
Supporting & Related Material· Jun 15, 2026
Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES→
Supporting & Related Material· Jun 15, 2026
Reference 26 - Neurotoxicity from intrathecal gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy→
Supporting & Related Material· Jun 15, 2026
Reference 28 - Skin-Related Adverse Reactions in Gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 29 - Acute lung injury following gadolinium contrast→
Supporting & Related Material· Jun 15, 2026
Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate→
Supporting & Related Material· Jun 15, 2026
Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing→
Supporting & Related Material· Jun 15, 2026
Reference 32 - Caught in the act Allergic-like reaction to→
Supporting & Related Material· Jun 15, 2026
Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent.→
Supporting & Related Material· Jun 15, 2026
Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media→
Supporting & Related Material· Jun 15, 2026
Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics→
Supporting & Related Material· Jun 15, 2026
Reference 36 - Effects of gadolinium→
Supporting & Related Material· Jun 15, 2026
Reference 37 - Gadolinium Contrast Agent Deposition in Children→
Supporting & Related Material· Jun 15, 2026
Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits→
Supporting & Related Material· Jun 15, 2026
Reference 39 - Delineating toxicity mechanisms associated with MRI contrast→
Supporting & Related Material· Jun 15, 2026
Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis→
Supporting & Related Material· Jun 15, 2026
Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide→
Supporting & Related Material· Jun 15, 2026
Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma→
Supporting & Related Material· Jun 15, 2026
Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention→